Hot Stock Update: Verastem, Inc. (NASDAQ:VSTM)

15

Verastem, Inc. (NASDAQ:VSTM) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Verastem, Inc. (NASDAQ:VSTM) lost -12.02 Percent and closed its previous trading session at $4.61. The stock traded with the average Volume of 877.65 Million at the end of last session.

The company reported its last earnings Actual EPS of $-0.43/share. While, the analyst predicted that the company could provide an EPS of $-0.42/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.01/share which shows an Earnings Surprise of -2.4 Percent.

Sell side analysts plays vital role in buying and selling a stock where 5 analysts rated Verastem, Inc. (NASDAQ:VSTM) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 5.58% where SMA50 and SMA200 are 23.01% and 23.89% respectively.

The company shows its Return on Assets (ROA) value of -107.1%. The Return on Equity (ROE) value stands at -163.6%.

Verastem, Inc. (NASDAQ:VSTM) currently has a Weekly Volatility of 7.83% percent while its Monthly Volatility is at 5.41% percent. While talking about Performance of the Stock, Verastem, Inc. currently has a Weekly performance of 8.98%, monthly performance percentage is 10.55 percent, Quarterly performance is 39.7 percent, 6 months performance shows a percent value of 35.99% and Yearly Performance is 96.17 percent.

Company Profile:

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company’s defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.

 

SHARE